The 10.7% gross margin in 2026Q2, down from 11.9% in 2025Q2, suggests that the revenue mix is increasingly weighted toward lower-margin risk contracts, consistent with the 56% revenue surge. Operating margin expanded to 3.5% from 3.1% year-over-year, but the absolute level remains thin, implying that SG&A costs are scaling nearly in line with revenue. The net margin of 2.0% is a slight improvement but still leaves the company highly sensitive to utilization spikes or claims cost inflation, as evidenced by the 0.71% net margin reported in the prior period.

ROIC has declined from 4.6% in 2024Q1 to 2.2% in 2026Q2, while ROE has similarly compressed from 3.4% to 3.4% over the same period, despite a doubling of total assets. This suggests that the $548.6M acquisition in 2025Q3 has not yet delivered the expected earnings uplift, and the goodwill-heavy balance sheet (goodwill at $887M, over 100% of equity) may be diluting returns. The modest 4.2% ROE, combined with a debt-to-equity of 1.64, implies that the company is leveraging up to fund growth that is currently earning below its cost of capital, a trend investors should monitor for signs of value creation or destruction.

DSO increased from 37 days in 2024Q1 to 46 days in 2026Q2, suggesting that the rapid revenue growth is accompanied by slower collections, possibly due to the complexity of capitated contracts. The current ratio has deteriorated from 1.51 to 1.23 over the same period, reflecting a tighter liquidity position as debt-funded acquisitions consume cash. The cash conversion cycle is not calculable due to missing DIO data, but the rising DSO and falling current ratio indicate that working capital efficiency is weakening, which could pressure cash flow if the trend continues.

The debt-to-equity ratio has nearly doubled from 0.96 to 1.64 over the last ten quarters, with total debt reaching $979.4M, reflecting the debt-financed acquisition strategy. Interest coverage has deteriorated from 4.16 in 2024Q1 to 2.70 in 2026Q2, suggesting that operating income is less sufficient to cover interest expenses, though still above the 1.0 threshold. The D/EBITDA ratio of 22.67 in 2026Q2 is elevated, but this is partly due to the low EBITDA margin; investors should monitor whether the raised guidance translates into EBITDA growth that can bring leverage down.

The current ratio has declined from 1.51 to 1.23 over the last ten quarters, suggesting that current liabilities are growing faster than current assets, partly due to increased medical claims payable. The quick ratio equals the current ratio at 1.23, indicating that inventory is not a significant factor, which is typical for a services-based model. While the $400.8M cash balance provides a buffer, the declining current ratio and rising debt levels suggest that liquidity could become strained if cash flows deteriorate or if the company continues to deploy cash into acquisitions.